양세훈 교수 연구실
article|
인용수 3
·2023
Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
Juwhan Choi, Chang‐Min Choi, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong‐Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Ji Young Park, Young‐Chul Kim, In‐Jae Oh, Chi Young Jung, Sang Hoon Lee, Seong Hoon Yoon, Sung Yong Lee, Tae Won Jang
IF 4Translational Lung Cancer Research
초록
Afatinib was effective in Korean patients with <i>EGFR</i> mutation-positive NSCLC with median OS over 4 years. The presence of baseline brain metastases and/or uncommon <i>EGFR</i> mutations were associated with reduced survival. In the absence of baseline brain metastases, median OS was more than 5 years.
키워드
AfatinibMedicineT790MInternal medicineLung cancerOncologyCohortEpidermal growth factor receptorRetrospective cohort studyClinical trial